Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia (CML-CP)

CME test	Downloadable PDF	PowerPoint slides	CME Information and Faculty Disclosures
Read Dr Love's original email (from July 26, 2010)			Subscribe to Dr Love's email alerts

Slides from a presentation at ASCO 2010 and transcribed comments from a recent interview with Hagop M Kantarjian, MD (6/30/10)

 

Kantarjian H et al. Dasatinib compared to imatinib in patients with newly diagnosed chronic myelogenous leukemia in chronic-phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study. Proc ASCO 2010;Abstract LBA6500.

Kantarjian H et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362(24):2260-70. Abstract

Go to previous Journal Club